An observational study in Non-Hodgkin Lymphoma Refractory/ Relapsed, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this prospective, non-therapeutic study is to evaluate molecular and clinical factors associated with clinical outcomes following CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engager (BiTE) therapies in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL).
This work builds on prior research from co-investigator Dr Sandeep Dave, in the Departments of Medicine and Engineering. The Dave lab has previously developed a clinically validated genetic assay for paired DNA and RNA sequencing (DuoSeq). More recently, the Dave lab utilized DuoSeq in a cohort of R/R NHL to identify and retrospectively validate a genomic signature associated with outcomes following CAR-T therapy. The primary goal of the proposed study is to prospectively validate this previously developed molecular signature in patients receiving CAR-T therapy. In addition, the proposed study aims to develop a complementary prognostic model for patients receiving BiTE therapy.
Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Duke inpatients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)
Number of participants who achieve complete remission (CR) following CAR-T therapy
Time frame: From enrollment to 360 days after CAR-T/BiTE therapy
Number of participants with progression-free survival (PFS) at 1 year
Time frame: From CAR-T treatment to documented disease progression or death from any cause, whichever occurs first (up to 1 year)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.